//Aspect Ratios for the Images

Investing in India’s Best
Product Startups

LEARN MORE
SigTuple
Eyestem
Mylo
Kissht
Scrut Automation
Qapita
Zluri
Sugar.Fit
Darwinbox
Darwinbox
Darwinbox
VIEW
READ

Mobile-first HRMS SaaS solution for the entire employee life cycle from hire-to-retire

Eyestem
Eyestem
VIEW
READ

Platform for development of globally scalable stem cell therapies for incurable diseases with its lead candidate targeting dry age-related macular degeneration

Kissht

Fintech company providing access to credit via transaction credit & personal loans

Mylo

Vertically integrated community led Health & Wellness platform catering to Mother and Baby care

Qapita

Digital Equity Management platform for private market companies with SaaS offering for captable / ESOP management and private market liquidity.

Scrut Automation
Scrut Automation
VIEW
READ

SaaS platform for information security compliance frameworks including SOC2, GDPR, ISO27001, HIPPA.

SigTuple
SigTuple
VIEW
READ

Platform for medical diagnosis through AI-powered analysis of visual medical data in Pathology

Sugar.Fit
Sugar.Fit
VIEW
READ

Personalized and easy to sustain digital management platform for diabetes and prediabetes patients

Zluri

Enterprise SaaS management platform enabling discovery, automation, optimization, and governance of SaaS stack across organization

Our Investment Focus

We invest in market creating business models and driven entrepreneurs to build lasting companies.

feature icon

Launchpad for Early Stage Startups

We endeavor to be a launchpad for early-stage product companies focussed on digital industry & intelligent mobility, digital health & life sciences, and enterprise digital adoption.

feature icon

Strong Fundamentals

We believe in businesses built on strong fundamentals & clear competitive advantage, and in growth that is profitable & sustainable.

feature icon

Large and Growing Markets

We look for large and growing markets, well defined problems, disruptive solutions, deep customer relationships and strong teams.

feature icon

Building for Scale

We seek to partner with entrepreneurs passionate about building in India, for the Globe.

OUR RISK TAKERS

OUR RISK TAKERS

"The best part about working with the Endiya team is the quality of advice we receive - it’s brutally pragmatic, actionable, and free of jargon. The fact that the team has worked in the trenches in building companies before is evident in every conversation."

Aayush Ghosh Choudhary

Scrut Automation

Aayush Ghosh Choudhary

OUR RISK TAKERS

OUR RISK TAKERS

"At Sugar.fit, our mission is to empower people with chronic diseases to live better and healthier lives. We’ve always believed that it is important to have investors who have domain knowledge and passion for healthcare and who understand the complex interplay between technology and healthcare and Endiya has been an ideal partner in enabling this."

Madan Somasundaram

Sugar.fit

Madan Somasundaram

OUR RISK TAKERS

OUR RISK TAKERS

"Endiya and Dr. Ramesh have been a guiding force for SigTuple, right from the Series A stage. His deep understanding of the medical industry has helped us hone our go-to-market strategy, reach key customers, and achieve product improvement."

Tathagato Rai Dastidar

SigTuple

Tathagato Rai Dastidar

OUR RISK TAKERS

OUR RISK TAKERS

"On the journey with Endiya, the three things which have been great for us are Sateesh as an enduring partner, an extended marketing arm & proactiveness in trying to help explore new areas of growth."

Ranvir Singh

Kissht

Ranvir Singh

OUR RISK TAKERS

OUR RISK TAKERS

"As Co-Founders, we have always sought investors who are thought partners and energize our mission. Sateesh and the Endiya team have been great companions in our journey building Qapita – ideating, guiding, executing, and above all encouraging us at every single step."

Ravi Ravulaparthi

Qapita

Ravi Ravulaparthi

OUR RISK TAKERS

OUR RISK TAKERS

"As entrepreneurs, we are always about here and now or maybe two days later, but Endiya’s investment team saw a little ahead and could caution & warn us at the right times to slow us down or push us to speedup."

Rohit Chennamaneni

Darwinbox

Rohit Chennamaneni

OUR RISK TAKERS

OUR RISK TAKERS

"Sateesh and the Endiya team have been giving us the right guidance on how to approach the market, customers, and growth. As an early-stage company, their inputs in the areas of building and shaping our business have been a huge advantage."

Ritish Reddy

Zluri

Ritish Reddy

OUR RISK TAKERS

OUR RISK TAKERS

"Endiya’s expertise in deep science makes them an ideal partner for Eyestem. Their wide networks enable them to provide unique insights and opportunities in the Biotech space. Added to that is Dr. Ramesh’s positive approach and encouragement, which have given strength to the team."

Dr. Jogin Desai

Eyestem

Dr. Jogin Desai

Endiya at a glance

We walk in early when the risk is highest and write the first cheque.

SEED ROUND,

MULTIPLE ROUNDS

FIRST CHEQUE UPTO

$2Mn

We are Thematic Investors
arrow right

Our thematic approach to investing combined with our collective experience inbuilding and scaling companies enables us to catch long-term, market-creating trends ahead of others.

LEARN MORE

ALMOST ALL
COMPANIES RAISE

FOLLOW-ON FUNDING

25x

CAPITAL RAISED BY PORTFOLIO

We are Operator VCs
arrow right

We bring deep domain expertise, vast entrepreneurial experience, and a global rolodex to help realize our portfolio’s growth potential.

LEARN MORE
feature icon
Digital Industry & Intelligent Mobility

Early investor in fabless semiconductors, edge AI, electric vehicles, and autonomous driving.

feature icon
Digital Health & Lifesciences

Investments across AI diagnosis, chronic disease management and cell therapy.

feature icon
Enterprise Digital Adoption

Deep bets in digital enterprise and infosec technology.

feature icon
Fintech

Category creating plays in digital lending, alternate investments & equity management for private markets.

In the News

SEE ALL
Lifesciences
SEE ALL
SEE ALL

Eyestem’s promising pipeline of products catches the eye of traditional pharma companies

Two pharmaceutical companies and a vaccine-maker invested in Eyestem (2022), putting the spotlight on the cell therapy company’s product pipeline. The six-year old company’s potential therapy for dry age-related macular degeneration, a global unmet medical need, awaits regulatory approvals in India for trial in humans, even as the company prepares to take the investigational new drug to Australia, says Eyestem co-founder and Chief Executive Jogin Desai.

Eyestem’s promising pipeline of products catches the eye of traditional pharma companies
AquaCulture
SEE ALL
SEE ALL

AquaExchange raises $6 m in Series A

AquaExchange, an aquaculture technology and fintech start-up, has raised $6 million in Series A funding led by Ocean 14 Capital with participation from existing investors including Endiya Partners and Accion Venture Lab.

AquaExchange raises $6 m in Series A
FinTech
SEE ALL
SEE ALL

Fintech Platform Grip Invest Snags $10 Mn From Multiple Investors in Series B Round

Fixed income investment platform Grip Invest has raised Rs 82 crore (around $10 million) in a Series B funding round. The round which saw a mix of equity and debt investments was led by venture debt firm Stride Ventures. The startup raised Rs 70 crore in equity funding, while the remaining Rs 12 crore was debt.

Fintech Platform Grip Invest Snags $10 Mn From Multiple Investors in Series B Round

Frequently Asked Questions

01
Endiya’s Focus
faq-accordion

We are an early-stage venture capital fund that invests in globally relevant product startups. Endiya’s portfolio consists of market-creating innovations and category-defining companies . We strive to partner with exceptional entrepreneurs with the talent to build world-class companies. Sectors that we focus on are:

Technology: DeepTech (fabless semiconductors, edge AI & intelligent mobility) and SaaS

Healthcare: Digital Health and Lifesciences

02
Investment Approach
faq-accordion

We primarily invest in seed & pre-series A rounds, with some room for flexibility on both ends.

With a focused investment approach and additional capital reserved for the follow-on rounds, we are committed to helping founders propel growth.

We contribute money, time, network, and resources to help you build. Given our focus and dedication, we like to have meaningful ownership.

03
Best Way to Connect with the Team
faq-accordion

The best way to approach us is through quality referrals (e.g. existing Portfolio Cos, Other entrepreneurs, Investors, Endiya Alums, Friends and Family etc).

04
Investment Process
faq-accordion

Having been entrepreneurs ourselves, we understand the gravity of swift decision making so that founders can focus on building their companies. While the duration of the investment process may vary, we typically try and decide within a month. At any time during the process, if we decide to pass on the opportunity, we communicate promptly. Broadly, this is what our investment process entails:

Review materials / pitch deck received from founders to assess preliminary fit with our investment focus.

Initial meetings: The Investment lead from Endiya conducts an introductory call to learn more about the idea, team and the opportunity. Subsequently, the investment lead spends more time to build their thesis and rationale and based on the interest takes the proposal to the partnership and team.

Endiya Team Meeting: In the next step, the founders are introduced to the Endiya leadership team for a conversation. Basis continued interest, we conduct our diligence calls.

IC Meeting: After the meeting with Endiya leadership, if all goes well, we present the investment proposal to our Investment Committee and revert with final feedback.

Know how we Work and Think

READ